 Charles Neff
Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2026 | 3193 | 1.970 |
Why?
| | Homosexuality, Male | 6 | 2026 | 231 | 1.300 |
Why?
| | Gastrointestinal Microbiome | 9 | 2026 | 767 | 1.260 |
Why?
| | HIV-1 | 11 | 2018 | 908 | 1.250 |
Why?
| | Aptamers, Nucleotide | 4 | 2023 | 87 | 1.210 |
Why?
| | Anti-Inflammatory Agents | 4 | 2022 | 477 | 1.010 |
Why?
| | CD4-Positive T-Lymphocytes | 10 | 2021 | 1140 | 0.840 |
Why?
| | Herpesvirus 1, Human | 1 | 2023 | 84 | 0.740 |
Why?
| | Cyclohexanes | 2 | 2011 | 22 | 0.670 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 373 | 0.630 |
Why?
| | Inflammation | 9 | 2026 | 2878 | 0.630 |
Why?
| | Microbiota | 6 | 2024 | 730 | 0.630 |
Why?
| | Triazoles | 2 | 2011 | 187 | 0.600 |
Why?
| | Interleukin-10 | 2 | 2022 | 309 | 0.580 |
Why?
| | Feces | 4 | 2025 | 495 | 0.540 |
Why?
| | Polysaccharides, Bacterial | 2 | 2022 | 69 | 0.520 |
Why?
| | Vagina | 4 | 2012 | 203 | 0.500 |
Why?
| | Viral Load | 4 | 2018 | 526 | 0.490 |
Why?
| | RNA, Small Interfering | 4 | 2012 | 637 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 919 | 0.470 |
Why?
| | Bacteria | 3 | 2022 | 765 | 0.440 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2021 | 409 | 0.420 |
Why?
| | Immune Tolerance | 1 | 2016 | 385 | 0.410 |
Why?
| | CCR5 Receptor Antagonists | 1 | 2011 | 6 | 0.340 |
Why?
| | B7-H1 Antigen | 4 | 2019 | 244 | 0.340 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2011 | 132 | 0.330 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2019 | 265 | 0.330 |
Why?
| | Anti-Infective Agents, Local | 1 | 2011 | 40 | 0.330 |
Why?
| | Pyrrolidinones | 1 | 2010 | 29 | 0.330 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2010 | 13 | 0.330 |
Why?
| | Leukocytes, Mononuclear | 5 | 2022 | 574 | 0.330 |
Why?
| | Anti-HIV Agents | 4 | 2016 | 912 | 0.320 |
Why?
| | Cytokines | 6 | 2021 | 2067 | 0.300 |
Why?
| | Sexual and Gender Minorities | 3 | 2022 | 259 | 0.280 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2021 | 166 | 0.270 |
Why?
| | Lung Diseases | 1 | 2015 | 780 | 0.270 |
Why?
| | Vitiligo | 2 | 2019 | 42 | 0.260 |
Why?
| | Mice | 18 | 2024 | 18329 | 0.230 |
Why?
| | Prevotella | 1 | 2025 | 26 | 0.230 |
Why?
| | Disease Models, Animal | 7 | 2024 | 4560 | 0.230 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 638 | 0.220 |
Why?
| | Animals | 22 | 2024 | 38030 | 0.220 |
Why?
| | Flow Cytometry | 6 | 2015 | 1162 | 0.220 |
Why?
| | Herpesvirus 3, Human | 2 | 2019 | 343 | 0.210 |
Why?
| | Humans | 38 | 2026 | 145474 | 0.210 |
Why?
| | Receptors, CCR5 | 2 | 2021 | 60 | 0.200 |
Why?
| | Herpesvirus 2, Human | 1 | 2023 | 27 | 0.200 |
Why?
| | Guinea Pigs | 1 | 2023 | 159 | 0.200 |
Why?
| | Interleukin-1 | 2 | 2019 | 961 | 0.190 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 468 | 0.190 |
Why?
| | Viral Envelope Proteins | 1 | 2023 | 98 | 0.190 |
Why?
| | Smokers | 2 | 2020 | 138 | 0.180 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1132 | 0.180 |
Why?
| | Antibodies, Viral | 2 | 2023 | 674 | 0.170 |
Why?
| | Immunity, Innate | 2 | 2019 | 835 | 0.170 |
Why?
| | Up-Regulation | 3 | 2019 | 847 | 0.160 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 109 | 0.160 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 6 | 0.160 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 76 | 0.150 |
Why?
| | Haplotypes | 2 | 2019 | 499 | 0.150 |
Why?
| | Immunophenotyping | 1 | 2020 | 319 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1217 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Female | 16 | 2026 | 78844 | 0.150 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2019 | 507 | 0.150 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 174 | 0.150 |
Why?
| | Adult | 11 | 2026 | 40777 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 17 | 0.140 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 523 | 0.140 |
Why?
| | Male | 14 | 2026 | 72842 | 0.140 |
Why?
| | Genes, MHC Class II | 1 | 2019 | 76 | 0.140 |
Why?
| | Dysbiosis | 2 | 2021 | 187 | 0.140 |
Why?
| | Disease | 1 | 2019 | 96 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 19 | 0.140 |
Why?
| | Mice, Transgenic | 3 | 2019 | 2188 | 0.140 |
Why?
| | Diet | 1 | 2026 | 1277 | 0.140 |
Why?
| | Lung | 4 | 2022 | 4106 | 0.140 |
Why?
| | Immune System | 1 | 2019 | 180 | 0.140 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 89 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 441 | 0.130 |
Why?
| | HIV | 1 | 2019 | 251 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2018 | 193 | 0.130 |
Why?
| | HIV-2 | 1 | 2016 | 18 | 0.130 |
Why?
| | Dideoxynucleosides | 1 | 2016 | 24 | 0.120 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 193 | 0.120 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2016 | 44 | 0.120 |
Why?
| | Lamivudine | 1 | 2016 | 65 | 0.120 |
Why?
| | Nitriles | 1 | 2018 | 207 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 133 | 0.120 |
Why?
| | Inflammasomes | 1 | 2018 | 144 | 0.120 |
Why?
| | Retroviridae Infections | 1 | 2015 | 47 | 0.110 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 103 | 0.110 |
Why?
| | HIV Antigens | 1 | 2015 | 17 | 0.110 |
Why?
| | Immune Evasion | 1 | 2015 | 61 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2016 | 202 | 0.110 |
Why?
| | Zimbabwe | 2 | 2026 | 76 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2018 | 506 | 0.110 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 224 | 0.110 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 220 | 0.110 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 675 | 0.110 |
Why?
| | Middle Aged | 10 | 2026 | 36215 | 0.110 |
Why?
| | Interleukin Receptor Common gamma Subunit | 2 | 2011 | 14 | 0.110 |
Why?
| | Down-Regulation | 2 | 2016 | 618 | 0.110 |
Why?
| | Gels | 2 | 2012 | 85 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2012 | 112 | 0.100 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2016 | 279 | 0.100 |
Why?
| | Housing, Animal | 1 | 2014 | 46 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 364 | 0.100 |
Why?
| | CD4 Lymphocyte Count | 2 | 2012 | 280 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 365 | 0.100 |
Why?
| | Receptors, Interleukin-1 | 1 | 2015 | 211 | 0.100 |
Why?
| | Software | 1 | 2019 | 680 | 0.100 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.100 |
Why?
| | Smoking | 1 | 2020 | 1472 | 0.100 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2012 | 55 | 0.100 |
Why?
| | Macrophages | 2 | 2018 | 1507 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2012 | 61 | 0.090 |
Why?
| | DNA-Binding Proteins | 4 | 2012 | 1480 | 0.090 |
Why?
| | Interleukin-1beta | 3 | 2021 | 389 | 0.090 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 204 | 0.090 |
Why?
| | Temperature | 1 | 2014 | 633 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1996 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1321 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 919 | 0.080 |
Why?
| | Raltegravir Potassium | 1 | 2010 | 18 | 0.080 |
Why?
| | Placebos | 1 | 2011 | 193 | 0.080 |
Why?
| | Mice, Inbred BALB C | 4 | 2016 | 1261 | 0.080 |
Why?
| | Host-Pathogen Interactions | 3 | 2024 | 361 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2378 | 0.080 |
Why?
| | Hematopoiesis | 1 | 2011 | 193 | 0.080 |
Why?
| | Lipopolysaccharides | 3 | 2019 | 858 | 0.070 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 340 | 0.070 |
Why?
| | Cell Lineage | 1 | 2011 | 377 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1329 | 0.070 |
Why?
| | Models, Genetic | 1 | 2011 | 524 | 0.070 |
Why?
| | Administration, Oral | 1 | 2010 | 866 | 0.070 |
Why?
| | Sindbis Virus | 1 | 2007 | 10 | 0.070 |
Why?
| | Mice, Knockout | 4 | 2021 | 3124 | 0.070 |
Why?
| | RNA, Viral | 2 | 2011 | 692 | 0.070 |
Why?
| | Nucleic Acid Conformation | 1 | 2011 | 723 | 0.070 |
Why?
| | Anti-Retroviral Agents | 2 | 2024 | 251 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 4295 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 435 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2015 | 3623 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2007 | 149 | 0.060 |
Why?
| | Antigens, CD | 2 | 2020 | 558 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5983 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2018 | 2382 | 0.060 |
Why?
| | Nanoparticles | 1 | 2011 | 517 | 0.060 |
Why?
| | Sexual Behavior | 2 | 2020 | 494 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1505 | 0.050 |
Why?
| | Young Adult | 5 | 2020 | 14218 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2011 | 769 | 0.050 |
Why?
| | Interleukin-6 | 2 | 2022 | 776 | 0.050 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2597 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2018 | 4148 | 0.050 |
Why?
| | Urban Population | 1 | 2026 | 493 | 0.050 |
Why?
| | Cohort Studies | 3 | 2019 | 6013 | 0.050 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2022 | 41 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 132 | 0.050 |
Why?
| | Bacteroides fragilis | 1 | 2022 | 14 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2022 | 115 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 161 | 0.040 |
Why?
| | Rural Population | 1 | 2026 | 659 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 3116 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 260 | 0.040 |
Why?
| | Ribonuclease III | 2 | 2011 | 43 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 123 | 0.040 |
Why?
| | Bacteroides | 1 | 2019 | 20 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 28 | 0.040 |
Why?
| | HLA-DQ beta-Chains | 1 | 2019 | 58 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2906 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2019 | 2803 | 0.040 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 89 | 0.040 |
Why?
| | Spondylarthritis | 1 | 2019 | 50 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 105 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2019 | 247 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2018 | 118 | 0.030 |
Why?
| | Aged | 4 | 2019 | 26153 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2019 | 320 | 0.030 |
Why?
| | Breast | 1 | 2018 | 156 | 0.030 |
Why?
| | Genetic Loci | 1 | 2019 | 264 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 4075 | 0.030 |
Why?
| | Base Sequence | 2 | 2012 | 2170 | 0.030 |
Why?
| | Caspase 1 | 1 | 2018 | 145 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 407 | 0.030 |
Why?
| | Protein Transport | 1 | 2019 | 442 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1048 | 0.030 |
Why?
| | Colon | 1 | 2020 | 309 | 0.030 |
Why?
| | Sulfones | 1 | 2018 | 127 | 0.030 |
Why?
| | Oxazines | 1 | 2016 | 37 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 234 | 0.030 |
Why?
| | Virus Diseases | 1 | 2019 | 216 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 42 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1082 | 0.030 |
Why?
| | Monocytes | 1 | 2019 | 539 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 588 | 0.030 |
Why?
| | Neuroglia | 1 | 2016 | 173 | 0.030 |
Why?
| | Retroviridae | 1 | 2015 | 100 | 0.030 |
Why?
| | Adolescent | 3 | 2020 | 22529 | 0.030 |
Why?
| | Herpesviridae Infections | 1 | 2016 | 148 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2019 | 499 | 0.030 |
Why?
| | Herpes Zoster | 1 | 2019 | 319 | 0.030 |
Why?
| | Immobilized Proteins | 1 | 2015 | 10 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 666 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 418 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 76 | 0.030 |
Why?
| | Brain | 2 | 2018 | 2947 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 209 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 364 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 337 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 191 | 0.030 |
Why?
| | Extracellular Space | 1 | 2015 | 117 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 170 | 0.030 |
Why?
| | Endotoxemia | 1 | 2015 | 86 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 418 | 0.030 |
Why?
| | Piperazines | 1 | 2016 | 375 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 264 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1852 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1044 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 378 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2015 | 762 | 0.020 |
Why?
| | Cold Temperature | 1 | 2014 | 206 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2014 | 202 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2014 | 266 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 679 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 881 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 523 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 855 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2012 | 132 | 0.020 |
Why?
| | Administration, Topical | 1 | 2012 | 153 | 0.020 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 6 | 0.020 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 25 | 0.020 |
Why?
| | Dendrimers | 1 | 2011 | 21 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1368 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 443 | 0.020 |
Why?
| | Peritoneum | 1 | 2011 | 43 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 89 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2011 | 87 | 0.020 |
Why?
| | Fibroblasts | 1 | 2016 | 1025 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2011 | 83 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2011 | 78 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2011 | 162 | 0.020 |
Why?
| | Viremia | 1 | 2011 | 160 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2011 | 128 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3155 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 971 | 0.020 |
Why?
| | Antibody Formation | 1 | 2011 | 288 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 344 | 0.020 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2009 | 4 | 0.020 |
Why?
| | SELEX Aptamer Technique | 1 | 2009 | 16 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 935 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2158 | 0.020 |
Why?
| | Interferon Type I | 1 | 2009 | 147 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 4316 | 0.020 |
Why?
| | Molecular Weight | 1 | 2007 | 312 | 0.020 |
Why?
| | Cricetinae | 1 | 2007 | 305 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5216 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2007 | 190 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1716 | 0.020 |
Why?
| | Aedes | 1 | 2007 | 66 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2015 | 2046 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6447 | 0.020 |
Why?
| | RNA Stability | 1 | 2007 | 107 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8333 | 0.010 |
Why?
| | Risk Factors | 1 | 2020 | 10885 | 0.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 699 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2883 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10077 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11853 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1896 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2823 | 0.010 |
Why?
| | Proteins | 1 | 2007 | 1023 | 0.010 |
Why?
| | Child | 1 | 2019 | 22707 | 0.010 |
Why?
|
|
Neff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|